Form 4: VolitionRX Ltd: Officer Rootsaert Receives Amended Stock Options

Rodney Gerard Rootsaert, Secretary of VolitionRX Ltd, received amended stock options on January 29, 2025, effectively replacing previously granted options.

Summary

• On January 29, 2025, Rodney Gerard Rootsaert, Secretary of VolitionRX Ltd, had his stock options amended.
• The transaction involved the cancellation of 'old' options and the grant of 'replacement' options.
• The 'old' options were originally granted on February 11, 2019, vested after 12 months, and were exercisable for five years.
• The 'replacement' options are fully vested and expire on February 11, 2029, ten years from the original grant date.
• The exercise price for both the old and replacement options is $3.25.
• The number of options involved in the transaction is 50,000.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting a routine stock option amendment. It's a standard corporate action with no inherent positive or negative implications for the company's overall prospects.

Positives

• The replacement options extend the expiration date by four years, providing more time for the officer to benefit from potential stock appreciation.

Industry Context

Stock option grants and amendments are a common practice in the biotechnology industry to incentivize and retain key personnel. The terms of these grants, such as vesting schedules and expiration dates, are often tailored to align with the company's long-term goals and the individual's contributions.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Regeneron routinely grant stock options to their executives and employees.
• The vesting schedules and expiration dates of these options vary, but a 10-year expiration date is not uncommon.

Stakeholder Impact

• The amended stock options could incentivize the officer to work towards increasing shareholder value.

Key Dates